{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T20:36:06Z","timestamp":1793306166767,"version":"4.5.0"},"reference-count":236,"publisher":"MDPI AG","issue":"22","license":[{"start":{"date-parts":[[2020,11,13]],"date-time":"2020-11-13T00:00:00Z","timestamp":1605225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Ministry of Science and Higher Education of Russian Federation","award":["\u2116 075-15-2020-792 (Unique identifier  RF----190220X0031)"],"award-info":[{"award-number":["\u2116 075-15-2020-792 (Unique identifier  RF----190220X0031)"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>Neuropsychiatric diseases are one of the main causes of disability, affecting millions of people. Various drugs are used for its treatment, although no effective therapy has been found yet. The blood brain barrier (BBB) significantly complicates drugs delivery to the target cells in the brain tissues. One of the problem-solving methods is the usage of nanocontainer systems. In this review we summarized the data about nanoparticles drug delivery systems and their application for the treatment of neuropsychiatric disorders. Firstly, we described and characterized types of nanocarriers: inorganic nanoparticles, polymeric and lipid nanocarriers, their advantages and disadvantages. We discussed ways to interact with nerve tissue and methods of BBB penetration. We provided a summary of nanotechnology-based pharmacotherapy of schizophrenia, bipolar disorder, depression, anxiety disorder and Alzheimer\u2019s disease, where development of nanocontainer drugs derives the most active. We described various experimental drugs for the treatment of Alzheimer\u2019s disease that include vector nanocontainers targeted on \u03b2-amyloid or tau-protein. Integrally, nanoparticles can substantially improve the drug delivery as its implication can increase BBB permeability, the pharmacodynamics and bioavailability of applied drugs. Thus, nanotechnology is anticipated to overcome the limitations of existing pharmacotherapy of psychiatric disorders and to effectively combine various treatment modalities in that direction.<\/jats:p>","DOI":"10.3390\/molecules25225294","type":"journal-article","created":{"date-parts":[[2020,11,13]],"date-time":"2020-11-13T10:32:47Z","timestamp":1605263567000},"page":"5294","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":154,"title":["Nano Carrier Drug Delivery Systems for the Treatment of Neuropsychiatric Disorders: Advantages and Limitations"],"prefix":"10.3390","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0247-2717","authenticated-orcid":false,"given":"Yana","family":"Zorkina","sequence":"first","affiliation":[{"name":"Department Basic and Applied Neurobiology, V.P. Serbsky Federal Medical Research Centre of Psychiatry and Narcology, 119034 Moscow, Russia"},{"name":"Healthcare Department, Mental-Health Clinic No. 1 Named after N.A. Alexeev of Moscow, 117152 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Abramova","sequence":"additional","affiliation":[{"name":"Department Basic and Applied Neurobiology, V.P. Serbsky Federal Medical Research Centre of Psychiatry and Narcology, 119034 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3480-910X","authenticated-orcid":false,"given":"Valeriya","family":"Ushakova","sequence":"additional","affiliation":[{"name":"Department Basic and Applied Neurobiology, V.P. Serbsky Federal Medical Research Centre of Psychiatry and Narcology, 119034 Moscow, Russia"},{"name":"Department of Biology, Lomonosov Moscow State University, 119992 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Morozova","sequence":"additional","affiliation":[{"name":"Department Basic and Applied Neurobiology, V.P. Serbsky Federal Medical Research Centre of Psychiatry and Narcology, 119034 Moscow, Russia"},{"name":"Healthcare Department, Mental-Health Clinic No. 1 Named after N.A. Alexeev of Moscow, 117152 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugene","family":"Zubkov","sequence":"additional","affiliation":[{"name":"Department Basic and Applied Neurobiology, V.P. Serbsky Federal Medical Research Centre of Psychiatry and Narcology, 119034 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marat","family":"Valikhov","sequence":"additional","affiliation":[{"name":"Department Basic and Applied Neurobiology, V.P. Serbsky Federal Medical Research Centre of Psychiatry and Narcology, 119034 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavel","family":"Melnikov","sequence":"additional","affiliation":[{"name":"Department Basic and Applied Neurobiology, V.P. Serbsky Federal Medical Research Centre of Psychiatry and Narcology, 119034 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Majouga","sequence":"additional","affiliation":[{"name":"D. Mendeleev University of Chemical Technology of Russia, 125047 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir","family":"Chekhonin","sequence":"additional","affiliation":[{"name":"Department Basic and Applied Neurobiology, V.P. Serbsky Federal Medical Research Centre of Psychiatry and Narcology, 119034 Moscow, Russia"},{"name":"Department of Medical Nanobiotechnology, Pirogov Russian National Research Medical University, 117997 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,11,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1016\/S0140-6736(18)32279-7","article-title":"Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990\u20132017: A systematic analysis for the Global Burden of Disease Study 2017","volume":"392","author":"James","year":"2018","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"197","DOI":"10.4103\/1673-5374.200796","article-title":"The exciting potential of nanotherapy in brain-tumor targeted drug delivery approaches","volume":"12","author":"Agrahari","year":"2017","journal-title":"Neural Regen. Res."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1021\/acsomega.8b03101","article-title":"Curcumin- and fish oil-loaded spongosome and cubosome nanoparticles with neuroprotective potential against H2O2-induced oxidative stress in differentiated human SH-SY5Y cells","volume":"4","author":"Rakotoarisoa","year":"2019","journal-title":"ACS Omega"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1158\/1078-0432.CCR-06-2854","article-title":"The blood-brain barrier and cancer: Transporters, treatment, and Trojan horses","volume":"13","author":"Deeken","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drup.2015.02.002","article-title":"Overcoming the blood\u2013brain tumor barrier for effective glioblastoma treatment","volume":"19","author":"Wesseling","year":"2015","journal-title":"Drug Resist. Updates"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Villabona-Rueda, A., Erice, C., Pardo, C.A., and Stins, M.F. (2019). The evolving concept of the blood brain barrier (BBB): From a single static barrier to a heterogeneous and dynamic relay center. Front. Cell. Neurosci., 13.","DOI":"10.3389\/fncel.2019.00405"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.nbd.2009.07.030","article-title":"Structure and function of the blood\u2013brain barrier","volume":"37","author":"Abbott","year":"2010","journal-title":"Neurobiol. Dis."},{"key":"ref_8","first-page":"167","article-title":"The blood-brain barrier challenge for the treatment of brain cancer, secondary brain metastases, and neurological diseases","volume":"12","author":"Weidle","year":"2015","journal-title":"Cancer Genom. Proteom."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/nrd725","article-title":"Drug and gene targeting to the brain with molecular Trojan horses","volume":"1","author":"Pardridge","year":"2002","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1017\/S1462399411001888","article-title":"Delivery of molecularly targeted therapy to malignant glioma, a disease of the whole brain","volume":"13","author":"Agarwal","year":"2011","journal-title":"Expert Rev. Mol. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"617","DOI":"10.2967\/jnumed.118.218792","article-title":"A Distinct advantage to intraarterial delivery of 89Zr-bevacizumab in PET imaging of mice with and without osmotic opening of the blood\u2013brain barrier","volume":"60","author":"Lesniak","year":"2018","journal-title":"J. Nucl. Med."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"C\u00f4t\u00e9, J., Bovenzi, V., Savard, M., Dubuc, C., Fortier, A., Neugebauer, W., Tremblay, L., M\u00fcller-Esterl, W., Tsanaclis, A.-M., and Lepage, M. (2012). Induction of selective blood-tumor barrier permeability and macromolecular transport by a biostable kinin B1 receptor agonist in a glioma rat model. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0037485"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"E10","DOI":"10.3171\/2015.1.FOCUS14767","article-title":"Novel delivery methods bypassing the blood-brain and blood-tumor barriers","volume":"38","author":"Hendricks","year":"2015","journal-title":"Neurosurg. Focus"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.2174\/1381612822666151221150733","article-title":"Evolving drug delivery strategies to overcome the blood brain barrier","volume":"22","author":"Hersh","year":"2016","journal-title":"Curr. Pharm. Des."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"S539","DOI":"10.4103\/2152-7806.187529","article-title":"Intrathecal baclofen therapy for spasticity: A compliance-based study to indicate effectiveness","volume":"7","author":"Alkhani","year":"2016","journal-title":"Surg. Neurol. Int."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.addr.2011.11.002","article-title":"Intranasal delivery of biologics to the central nervous system","volume":"64","author":"Lochhead","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1080\/1061186X.2016.1184272","article-title":"Nano carriers for drug transport across the blood\u2013brain barrier","volume":"25","author":"Li","year":"2017","journal-title":"J. Drug Target."},{"key":"ref_18","first-page":"73","article-title":"Nanoparticles: Cellular uptake and cytotoxicity","volume":"811","author":"Adjei","year":"2014","journal-title":"Atherosclerosis"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1039\/C5MD00038F","article-title":"Selective neuronal targeting, protection and signaling network analysis via dopamine-mediated mesoporous silica nanoparticles","volume":"6","author":"Zhang","year":"2015","journal-title":"MedChemComm"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/nbt.1807","article-title":"Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes","volume":"29","author":"Seow","year":"2011","journal-title":"Nat. Biotechnol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"6972","DOI":"10.1074\/jbc.M805956200","article-title":"Functional protein delivery into neurons using polymeric nanoparticles","volume":"284","author":"Hasadsri","year":"2009","journal-title":"J. Biol. Chem."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1002\/iub.1223","article-title":"Role of astrocytes in major neurological disorders: The evidence and implications","volume":"65","author":"Scuderi","year":"2013","journal-title":"IUBMB Life"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.biomaterials.2015.03.044","article-title":"Myelin repair in vivo is increased by targeting oligodendrocyte precursor cells with nanoparticles encapsulating leukaemia inhibitory factor (LIF)","volume":"56","author":"Rittchen","year":"2015","journal-title":"Biomaterials"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1021\/nn901869f","article-title":"Microglial response to gold nanoparticles","volume":"4","author":"Hutter","year":"2010","journal-title":"ACS Nano"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"150","DOI":"10.7150\/thno.9476","article-title":"Macrophage targeted theranostics as personalized nanomedicine strategies for inflammatory diseases","volume":"5","author":"Patel","year":"2015","journal-title":"Theranostics"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"9881","DOI":"10.1021\/nn4036014","article-title":"Selective nanovector mediated treatment of activated proinflammatory microglia\/macrophages in spinal cord injury","volume":"7","author":"Papa","year":"2013","journal-title":"ACS Nano"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1016\/j.biomaterials.2008.12.077","article-title":"Nanoparticle-mediated local delivery of methylprednisolone after spinal cord injury","volume":"30","author":"Kim","year":"2009","journal-title":"Biomaterials"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1615\/CritRevTherDrugCarrierSyst.2018024697","article-title":"Updated progress of nanocarrier-based intranasal drug delivery systems for treatment of brain diseases","volume":"35","author":"Fan","year":"2018","journal-title":"Crit. Rev. Ther. Drug Carr. Syst."},{"key":"ref_29","first-page":"4981","article-title":"Nanotechnology-based drug delivery systems for the treatment of Alzheimer\u2019s disease","volume":"10","author":"Chorilli","year":"2015","journal-title":"Int. J. Nanomed."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/S1734-1140(12)70901-5","article-title":"Nanoparticles as drug delivery systems","volume":"64","author":"Wilczewska","year":"2012","journal-title":"Pharmacol. Rep."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.jconrel.2017.12.015","article-title":"Crossing the blood-brain barrier with nanoparticles","volume":"270","author":"Zhou","year":"2018","journal-title":"J. Control. Release"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jconrel.2016.11.025","article-title":"Nanotechnology-based drug delivery systems for Alzheimer\u2019s disease management: Technical, industrial, and clinical challenges","volume":"245","author":"Wen","year":"2017","journal-title":"J. Control. Release"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1080\/17425247.2018.1471058","article-title":"Recent advancements in the field of nanotechnology for the delivery of anti-Alzheimer drug in the brain region","volume":"15","author":"Agrawal","year":"2018","journal-title":"Expert Opin. Drug Deliv."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.addr.2019.07.010","article-title":"Nanocarrier-based systems for targeted and site specific therapeutic delivery","volume":"144","author":"Majumder","year":"2019","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Shah, P., Chavda, K., Vyas, B., and Patel, S. (2020). Formulation development of linagliptin solid lipid nanoparticles for oral bioavailability enhancement: Role of P-gp inhibition. Drug Deliv. Transl. Res., 1\u201320.","DOI":"10.1007\/s13346-020-00839-9"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Mathew, A., Fukuda, T., Nagaoka, Y., Hasumura, T., Morimoto, H., Yoshida, Y., Maekawa, T., Venugopal, K., and Kumar, D.S. (2012). Curcumin loaded-PLGA nanoparticles conjugated with Tet-1 peptide for potential use in Alzheimer\u2019s disease. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0032616"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Teleanu, D.M., Chircov, C., Grumezescu, A.M., Volceanov, A., and Teleanu, R.I. (2018). Blood-brain delivery methods using nanotechnology. Pharmaceutics, 10.","DOI":"10.3390\/pharmaceutics10040269"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.ijpharm.2018.04.032","article-title":"PAMAM dendrimers as a carbamazepine delivery system for neurodegenerative diseases: A biophysical and nanotoxicological characterization","volume":"544","author":"Martinez","year":"2018","journal-title":"Int. J. Pharm."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jconrel.2012.03.020","article-title":"Doxil\u00ae\u2014The first FDA-approved nano-drug: Lessons learned","volume":"160","author":"Barenholz","year":"2012","journal-title":"J. Control. Release"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0076-6879(09)65007-2","article-title":"Microfluidic methods for production of liposomes","volume":"465","author":"Yu","year":"2009","journal-title":"Methods Enzymol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"25876","DOI":"10.1038\/srep25876","article-title":"Liposome production by microfluidics: Potential and limiting factors","volume":"6","author":"Carugo","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.2217\/nnm.13.118","article-title":"Current trends in the use of liposomes for tumor targeting","volume":"8","author":"Deshpande","year":"2013","journal-title":"Nanomedicine"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.4155\/fmc.09.137","article-title":"Novel and emerging strategies in drug delivery for overcoming the blood\u2013brain barrier","volume":"1","author":"Stenehjem","year":"2009","journal-title":"Futur. Med. Chem."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.jconrel.2005.08.012","article-title":"The role of dioleoylphosphatidylethanolamine (DOPE) in targeted gene delivery with mannosylated cationic liposomes via intravenous route","volume":"108","author":"Hattori","year":"2005","journal-title":"J. Control. Release"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"4102","DOI":"10.1002\/smll.201670150","article-title":"Gold nanoshells: Combined near infrared photothermal therapy and chemotherapy using gold nanoshells coated liposomes to enhance antitumor effect (Small 30\/2016)","volume":"12","author":"Luo","year":"2016","journal-title":"Small"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s11095-015-1774-3","article-title":"In vivo functional evaluation of increased brain delivery of the opioid peptide DAMGO by glutathione-PEGylated liposomes","volume":"33","author":"Lindqvist","year":"2016","journal-title":"Pharm. Res."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.jconrel.2017.08.033","article-title":"Advances in the design of solid lipid nanoparticles and nanostructured lipid carriers for targeting brain diseases","volume":"264","author":"Tapeinos","year":"2017","journal-title":"J. Control. Release"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1002\/anie.201002969","article-title":"PEGylated inorganic nanoparticles","volume":"50","author":"Karakoti","year":"2011","journal-title":"Angew. Chem. Int. Ed."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1039\/b920570p","article-title":"PEGylated polymers for medicine: From conjugation to self-assembled systems","volume":"46","author":"Joralemon","year":"2010","journal-title":"Chem. Commun."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"3304","DOI":"10.1021\/nn300240p","article-title":"Receptor-mediated delivery of magnetic nanoparticles across the blood\u2013brain barrier","volume":"6","author":"Qiao","year":"2012","journal-title":"ACS Nano"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3389\/fncel.2020.00021","article-title":"Application of iron oxide nanoparticles in the diagnosis and treatment of neurodegenerative diseases with emphasis on Alzheimer\u2019s disease","volume":"14","author":"Luo","year":"2020","journal-title":"Front. Cell. Neurosci."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1021\/ja411096m","article-title":"68Ga-Labeled gold glyconanoparticles for exploring blood\u2013brain barrier permeability: Preparation, biodistribution studies, and improved brain uptake via neuropeptide conjugation","volume":"136","author":"Frigell","year":"2013","journal-title":"J. Am. Chem. Soc."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.pnpbp.2017.04.008","article-title":"The recent progress in animal models of depression","volume":"77","author":"Wang","year":"2017","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.neubiorev.2014.07.005","article-title":"Making room for oxytocin in understanding depression","volume":"45","author":"McQuaid","year":"2014","journal-title":"Neurosci. Biobehav. Rev."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ejphar.2014.07.046","article-title":"Faster, better, stronger: Towards new antidepressant therapeutic strategies","volume":"753","author":"Dinan","year":"2015","journal-title":"Eur. J. Pharmacol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1080\/10717544.2018.1529209","article-title":"Design, characterization and in vivo evaluation of nanostructured lipid carriers (NLC) as a new drug delivery system for hydrochlorothiazide oral administration in pediatric therapy","volume":"25","author":"Cirri","year":"2018","journal-title":"Drug Deliv."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1016\/j.drudis.2019.06.001","article-title":"Antidepressants and nose-to-brain delivery: Drivers, restraints, opportunities and challenges","volume":"24","author":"Vitorino","year":"2019","journal-title":"Drug Discov. Today"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"683","DOI":"10.4155\/tde-2019-0060","article-title":"Formulation of polymeric nanoparticles of antidepressant drug for intranasal delivery","volume":"10","author":"Jani","year":"2019","journal-title":"Ther. Deliv."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1080\/03639045.2020.1757697","article-title":"Effect of binary combinations of solvent systems on permeability profiling of pure agomelatine across rat skin: A comparative study with statistically optimized polymeric nanoparticles","volume":"46","author":"Shinde","year":"2020","journal-title":"Drug Dev. Ind. Pharm."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.apsb.2017.11.012","article-title":"Surface modification of PGP for a neutrophil\u2013nanoparticle co-vehicle to enhance the anti-depressant effect of baicalein","volume":"8","author":"Chen","year":"2018","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Harris, N.M., Ritzel, R., Mancini, N.S., Jiang, Y., Yi, X., Manickam, D.S., Banks, W.A., Kabanov, A.V., McCullough, L.D., and Verma, R. (2016). Nano-particle delivery of brain derived neurotrophic factor after focal cerebral ischemia reduces tissue injury and enhances behavioral recovery. Pharmacol. Biochem. Behav., 48\u201356.","DOI":"10.1016\/j.pbb.2016.09.003"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"4975","DOI":"10.2147\/IJN.S109088","article-title":"Antidepressant effects of curcumin and HU-211 coencapsulated solid lipid nanoparticles against corticosterone-induced cellular and animal models of major depression","volume":"11","author":"He","year":"2016","journal-title":"Int. J. Nanomed."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1159\/000480001","article-title":"Targeting the endocannabinoid\/CB1 receptor system for treating major depression through antidepressant activities of curcumin and dexanabinol-loaded solid lipid nanoparticles","volume":"42","author":"He","year":"2017","journal-title":"Cell Physiol. Biochem."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.neuroscience.2019.09.032","article-title":"Curcumin-loaded nanocapsules reverses the depressant-like behavior and oxidative stress induced by \u03b2-amyloid in mice","volume":"423","author":"Fidelis","year":"2019","journal-title":"Neuroscience"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ijpharm.2014.05.004","article-title":"Pharmacoscintigraphic evaluation of potential of lipid nanocarriers for nose-to-brain delivery of antidepressant drug","volume":"470","author":"Alam","year":"2014","journal-title":"Int. J. Pharm."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"270","DOI":"10.2174\/15701638113109990031","article-title":"Formulation and evaluation of niosomal nasal drug delivery system of folic acid for brain targeting","volume":"10","author":"Ravouru","year":"2013","journal-title":"Curr. Drug Discov. Technol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s40204-017-0076-8","article-title":"Nanoparticulated polymeric composites enfolding lithium carbonate as brain drug in persuading depression: An in vivo study","volume":"6","author":"Margret","year":"2017","journal-title":"Prog. Biomater."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.ijbiomac.2013.04.011","article-title":"Evaluation of safety and efficacy of brain targeted chitosan nanoparticles of minocycline","volume":"59","author":"Nagpal","year":"2013","journal-title":"Int. J. Biol. Macromol."},{"key":"ref_69","first-page":"1","article-title":"Pharmacological evaluation of nasal delivery of selegiline hydrochloride-loaded thiolated chitosan nanoparticles for the treatment of depression","volume":"44","author":"Singh","year":"2015","journal-title":"Artif. Cells Nanomed. Biotechnol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1177\/0269881119836221","article-title":"Silymarin and silymarin nanoparticles guard against chronic unpredictable mild stress induced depressive-like behavior in mice: Involvement of neurogenesis and NLRP3 inflammasome","volume":"33","author":"Ashraf","year":"2019","journal-title":"J. Psychopharmacol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1080\/21691401.2018.1451873","article-title":"Formulation and evaluation of nano lipid formulation containing CNS acting drug: Molecular docking, in-vitro assessment and bioactivity detail in rats","volume":"46","author":"Alam","year":"2018","journal-title":"Artif. Cells Nanomed. Biotechnol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"275","DOI":"10.3109\/1061186X.2014.994097","article-title":"Brain delivery of intranasalin situgel of nanoparticulated polymeric carriers containing antidepressant drug: Behavioral and biochemical assessment","volume":"23","author":"Kaur","year":"2014","journal-title":"J. Drug Target."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.nano.2014.09.012","article-title":"Monocyte mediated brain targeting delivery of macromolecular drug for the therapy of depression","volume":"11","author":"Qin","year":"2015","journal-title":"Nanomed. Nanotechnol. Biol. Med."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.carbpol.2012.02.051","article-title":"Venlafaxine loaded chitosan NPs for brain targeting: Pharmacokinetic and pharmacodynamic evaluation","volume":"89","author":"Haque","year":"2012","journal-title":"Carbohydr. Polym."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1080\/17425247.2019.1690452","article-title":"In vivo biodistribution of venlafaxine-PLGA nanoparticles for brain delivery: Plain vs. functionalized nanoparticles","volume":"16","author":"Gomes","year":"2019","journal-title":"Expert Opin. Drug Deliv."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jpsychires.2013.10.011","article-title":"Development and evaluation of brain targeted intranasal alginate nanoparticles for treatment of depression","volume":"48","author":"Haque","year":"2014","journal-title":"J. Psychiatr. Res."},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Grabrucker, A.M., Garner, C.C., Boeckers, T.M., Bondioli, L., Ruozi, B., Forni, F., Vandelli, M.A., and Tosi, G. (2011). Development of novel Zn2+ loaded nanoparticles designed for cell-type targeted drug release in CNS neurons: In vitro evidences. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0017851"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"608","DOI":"10.3389\/fnins.2017.00608","article-title":"Iron oxide nanoparticle delivery of peptides to the brain: Reversal of anxiety during drug withdrawal","volume":"11","author":"Vinzant","year":"2017","journal-title":"Front. Neurosci."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ijbiomac.2015.07.041","article-title":"Brain delivery of buspirone hydrochloride chitosan nanoparticles for the treatment of general anxiety disorder","volume":"81","author":"Bari","year":"2015","journal-title":"Int. J. Biol. Macromol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1208\/s12249-018-1211-0","article-title":"Buspirone hydrochloride loaded in situ nanovesicular gel as an anxiolytic nasal drug delivery system: In vitro and animal studies","volume":"20","author":"Abdelnabi","year":"2019","journal-title":"AAPS PharmSciTech"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40580-016-0061-2","article-title":"Polymeric nanoparticles containing diazepam: Preparation, optimization, characterization, in-vitro drug release and release kinetic study","volume":"3","author":"Bohrey","year":"2016","journal-title":"Nano Converg."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ijbiomac.2013.03.022","article-title":"Optimization of brain targeted gallic acid nanoparticles for improved antianxiety-like activity","volume":"57","author":"Nagpal","year":"2013","journal-title":"Int. J. Biol. Macromol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1208\/s12249-017-0944-5","article-title":"Enhancement of in vivo efficacy and oral bioavailability of aripiprazole with solid lipid nanoparticles","volume":"19","author":"Sinha","year":"2018","journal-title":"AAPS PharmSciTech"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.msec.2016.04.089","article-title":"Aripiprazole loaded poly(caprolactone) nanoparticles: Optimization and in vivo pharmacokinetics","volume":"66","author":"Sawant","year":"2016","journal-title":"Mater. Sci. Eng. C"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.ijbiomac.2017.11.031","article-title":"Glycol chitosan functionalized asenapine nanostructured lipid carriers for targeted brain delivery: Pharmacokinetic and teratogenic assessment","volume":"108","author":"Singh","year":"2018","journal-title":"Int. J. Biol. Macromol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"221","DOI":"10.3109\/08982104.2015.1098659","article-title":"Nano-transfersomal formulations for transdermal delivery of asenapine maleate: In vitro and in vivo performance evaluations","volume":"26","author":"Shreya","year":"2015","journal-title":"J. Liposome Res."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ejpb.2014.02.007","article-title":"Haloperidol-loaded intranasally administered lectin functionalized poly(ethylene glycol)\u2013block-poly(d,l)-lactic-co-glycolic acid (PEG\u2013PLGA) nanoparticles for the treatment of schizophrenia","volume":"87","author":"Piazza","year":"2014","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.etap.2018.05.017","article-title":"Lithium entrapped chitosan nanoparticles to reduce toxicity and increase cellular uptake of lithium","volume":"61","author":"Narayan","year":"2018","journal-title":"Environ. Toxicol. Pharmacol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1080\/03639045.2019.1593434","article-title":"Fabrication of solid lipid nanoparticles of lurasidone HCl for oral delivery: Optimization, in vitro characterization, cell line studies and in vivo efficacy in schizophrenia","volume":"45","author":"Patel","year":"2019","journal-title":"Drug Dev. Ind. Pharm."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"3082","DOI":"10.1016\/j.xphs.2019.05.001","article-title":"Optimization of nanostructured lipid carriers of lurasidone hydrochloride using box-behnken design for brain targeting: In vitro and in vivo studies","volume":"108","author":"Jazuli","year":"2019","journal-title":"J. Pharm. Sci."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1007\/s13346-019-00702-6","article-title":"Exploring micellar-based polymeric systems for effective nose-to-brain drug delivery as potential neurotherapeutics","volume":"10","author":"Pokharkar","year":"2019","journal-title":"Drug Deliv. Transl. Res."},{"key":"ref_92","first-page":"1","article-title":"Enhanced brain targeting efficacy of Olanzapine through solid lipid nanoparticles","volume":"45","author":"Natarajan","year":"2016","journal-title":"Artif. Cells Nanomed. Biotechnol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1208\/s12249-018-1213-y","article-title":"Agranulocytosis-protective olanzapine-loaded nanostructured lipid carriers engineered for CNS delivery: Optimization and hematological toxicity studies","volume":"20","author":"Gadhave","year":"2019","journal-title":"AAPS PharmSciTech"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.ijpharm.2013.04.084","article-title":"Brain targeting of olanzapine via intranasal delivery of core\u2013shell difunctional block copolymer mixed nanomicellar carriers: In vitro characterization, ex vivo estimation of nasal toxicity and in vivo biodistribution studies","volume":"452","author":"Abdelbary","year":"2013","journal-title":"Int. J. Pharm."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1166\/jbn.2015.2078","article-title":"Mucoadhesive amphiphilic methacrylic copolymer-functionalized poly(\u03b5-caprolactone) nanocapsules for nose-to-brain delivery of olanzapine","volume":"11","author":"Fonseca","year":"2015","journal-title":"J. Biomed. Nanotechnol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1208\/s12249-014-0189-5","article-title":"Intranasal drug delivery of olanzapine-loaded chitosan nanoparticles","volume":"15","author":"Baltzley","year":"2014","journal-title":"AAPS PharmSciTech"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"4169","DOI":"10.1016\/j.actbio.2011.07.025","article-title":"Development and evaluation of olanzapine-loaded PLGA nanoparticles for nose-to-brain delivery: In vitro and in vivo studies","volume":"7","author":"Seju","year":"2011","journal-title":"Acta Biomater."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1208\/s12249-016-0657-1","article-title":"Paliperidone-loaded nanolipomer system for sustained delivery and enhanced intestinal permeation: Superiority to polymeric and solid lipid nanoparticles","volume":"18","author":"Helal","year":"2016","journal-title":"AAPS PharmSciTech"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1208\/s12249-017-0844-8","article-title":"Development and evaluation of pH-responsive cyclodextrin-based in situ gel of paliperidone for intranasal delivery","volume":"19","author":"Sherje","year":"2017","journal-title":"AAPS PharmSciTech"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"230","DOI":"10.3109\/10717544.2014.909907","article-title":"Solubilized delivery of paliperidone palmitate by d-alpha-tocopheryl polyethylene glycol 1000 succinate micelles for improved short-term psychotic management","volume":"23","author":"Muthu","year":"2014","journal-title":"Drug Deliv."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"346","DOI":"10.3109\/10717544.2014.914602","article-title":"Paliperidone microemulsion for nose-to-brain targeted drug delivery system: Pharmacodynamic and pharmacokinetic evaluation","volume":"23","author":"Patel","year":"2014","journal-title":"Drug Deliv."},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Lugasi, L., Grinberg, I., Sabag, R., Madar, R., Einat, H., and Margel, S. (2020). Proteinoid nanocapsules as drug delivery system for improving antipsychotic activity of risperidone. Molecules, 25.","DOI":"10.3390\/molecules25174013"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1080\/03639045.2019.1619759","article-title":"Formulation and biopharmaceutical evaluation of risperidone-loaded chitosan nanoparticles for intranasal delivery","volume":"45","author":"Rukmangathen","year":"2019","journal-title":"Drug Dev. Ind. Pharm."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"468","DOI":"10.3109\/1061186X.2010.523787","article-title":"Brain targeting of risperidone-loaded solid lipid nanoparticles by intranasal route","volume":"19","author":"Patel","year":"2010","journal-title":"J. Drug Target."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1080\/10611860802476504","article-title":"Mucoadhesive nanoemulsion-based intranasal drug delivery system of olanzapine for brain targeting","volume":"16","author":"Kumar","year":"2008","journal-title":"J. Drug Target."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.lfs.2016.08.033","article-title":"Development of risperidone liposomes for brain targeting through intranasal route","volume":"163","author":"Narayan","year":"2016","journal-title":"Life Sci."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"123","DOI":"10.2174\/1567201815666181011121750","article-title":"Formulation and evaluation of neuroactive drug loaded chitosan nanoparticle for nose to brain delivery: In-vitro characterization and in-vivo behavior study","volume":"16","author":"Qureshi","year":"2018","journal-title":"Curr. Drug Deliv."},{"key":"ref_108","first-page":"17590","article-title":"Preparation and brain delivery of nasal solid lipid nanoparticles of quetiapine fumarate in situ gel in rat model of schizophrenia","volume":"8","author":"Li","year":"2015","journal-title":"Int. J. Clin. Exp. Med."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1208\/s12249-016-0552-9","article-title":"Quetiapine nanoemulsion for intranasal drug delivery: Evaluation of brain-targeting efficiency","volume":"18","author":"Boche","year":"2016","journal-title":"AAPS PharmSciTech"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.jsps.2016.07.003","article-title":"Direct and enhanced delivery of nanoliposomes of anti schizophrenic agent to the brain through nasal route","volume":"25","author":"Upadhyay","year":"2017","journal-title":"Saudi Pharm. J."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.ejps.2016.05.008","article-title":"Non-invasive intranasal delivery of quetiapine fumarate loaded microemulsion for brain targeting: Formulation, physicochemical and pharmacokinetic consideration","volume":"91","author":"Shah","year":"2016","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.ijbiomac.2016.04.076","article-title":"Application of box-behnken design for optimization and development of quetiapine fumarate loaded chitosan nanoparticles for brain delivery via intranasal route","volume":"89","author":"Shah","year":"2016","journal-title":"Int. J. Biol. Macromol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2014\/847547","article-title":"Formulation and evaluation of thermosensitive biogels for nose to brain delivery of doxepin","volume":"2014","author":"Naik","year":"2014","journal-title":"BioMed Res. Int."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"25102","DOI":"10.1088\/0957-4484\/27\/2\/025102","article-title":"Intranasal delivery of paroxetine nanoemulsion via the olfactory region for the management of depression: Formulation, behavioural and biochemical estimation","volume":"27","author":"Pandey","year":"2016","journal-title":"Nanotechnology"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"107","DOI":"10.30827\/ars.v58i3.6528","article-title":"Quality by design (QbD) approach to formulate in situ gelling system for nose to brain delivery of Fluoxetine hydrochloride: Ex-vivo and In-vivo study","volume":"58","author":"Pathan","year":"2017","journal-title":"ARS Pharm."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1007\/s13346-018-0506-8","article-title":"Composite carbohydrate interpenetrating polyelectrolyte nano-complexes (IPNC) as a controlled oral delivery system of citalopram HCl for pediatric use: In-vitro\/in-vivo evaluation and histopathological examination","volume":"8","author":"Kamel","year":"2018","journal-title":"Drug Deliv. Transl. Res."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"162","DOI":"10.2174\/2211738507666190327145628","article-title":"Systematic development of sertraline loaded solid lipid nanoparticle (SLN) by emulsification-ultrasonication method and pharmacokinetic study in sprague-dawley rats","volume":"7","author":"Rahman","year":"2019","journal-title":"Pharm. Nanotechnol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1208\/s12249-012-9893-1","article-title":"Thermoreversible nasal in situ gel of venlafaxine hydrochloride: Formulation, characterization, and pharmacodynamic evaluation","volume":"14","author":"Bhandwalkar","year":"2012","journal-title":"AAPS PharmSciTech"},{"key":"ref_119","doi-asserted-by":"crossref","unstructured":"Aranaz, I., Pa\u00f1os, I., Peniche, C., Heras, A., and Acosta, N. (2017). Chitosan spray-dried microparticles for controlled delivery of venlafaxine hydrochloride. Molecules, 22.","DOI":"10.3390\/molecules22111980"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.jsps.2016.12.003","article-title":"Development and evaluation of Desvenlafaxine loaded PLGA-chitosan nanoparticles for brain delivery","volume":"25","author":"Tong","year":"2016","journal-title":"Saudi Pharm. J."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jddst.2015.09.020","article-title":"Controlled release of antidepressant drugs by multiple stimuli-sensitive hydrogels based on \u03b1-aminoacid residues","volume":"30","author":"Casolaro","year":"2015","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"ref_122","doi-asserted-by":"crossref","unstructured":"Mitroshina, E.V., Mishchenko, T.A., Usenko, A.V., Epifanova, E.A., Yarkov, R.S., Gavrish, M.S., Babaev, A.A., and Vedunova, M.V. (2018). AAV-Syn-BDNF-EGFP virus construct exerts neuroprotective action on the hippocampal neural network during hypoxia in vitro. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19082295"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"22404","DOI":"10.1038\/srep22404","article-title":"intranasal delivery of recombinant AAV containing BDNF fused with HA2TAT: A potential promising therapy strategy for major depressive disorder","volume":"6","author":"Ma","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1038\/sj.mp.4001992","article-title":"Molecular studies of major depressive disorder: The epigenetic perspective","volume":"12","author":"Mill","year":"2007","journal-title":"Mol. Psychiatry"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"93","DOI":"10.31887\/DCNS.2017.19.2\/bbandelow","article-title":"Treatment of anxiety disorders","volume":"19","author":"Bandelow","year":"2017","journal-title":"Dialogues Clin. Neurosci."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1002\/da.20329","article-title":"Novel treatment approaches for refractory anxiety disorders","volume":"25","author":"Pollack","year":"2008","journal-title":"Depression Anxiety"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.brainres.2012.04.032","article-title":"Buspirone: What is it all about?","volume":"1461","author":"Loane","year":"2012","journal-title":"Brain Res."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.neubiorev.2015.10.013","article-title":"Sex\/gender differences in the brain and cognition in schizophrenia","volume":"67","author":"Mendrek","year":"2016","journal-title":"Neurosci. Biobehav. Rev."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.ogc.2018.05.002","article-title":"Treatment of peripartum bipolar disorder","volume":"45","author":"Clark","year":"2018","journal-title":"Obstet. Gynecol. Clin. N. Am."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/7854_2010_46","article-title":"Antipsychotic dosing and drug delivery","volume":"Volume 4","author":"Swerdlow","year":"2010","journal-title":"Behavioral Neurobiology of Schizophrenia and Its Treatment"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3109\/10611860008996856","article-title":"Schizophrenia and drug delivery systems","volume":"8","author":"Cheng","year":"2000","journal-title":"J. Drug Target."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"s63","DOI":"10.1192\/bjp.195.52.s63","article-title":"Clinical guideline recommendations for antipsychotic long-acting injections","volume":"195","author":"Kane","year":"2009","journal-title":"Br. J. Psychiatry"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.ejps.2017.03.050","article-title":"Design and in vivo evaluation of solid lipid nanoparticulate systems of Olanzapine for acute phase schizophrenia treatment: Investigations on antipsychotic potential and adverse effects","volume":"104","author":"Joseph","year":"2017","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.ijbiomac.2018.01.121","article-title":"Enhanced oral bioavailability of an antipsychotic drug through nanostructured lipid carriers","volume":"110","author":"Jawahar","year":"2018","journal-title":"Int. J. Biol. Macromol."},{"key":"ref_135","first-page":"175","article-title":"Development of olanzapine loaded PNA microgels for depot drug delivery in treatment of schizophrenia: In vitro an in vivo release profile","volume":"73","author":"Pervaiz","year":"2016","journal-title":"Acta Pol. Pharm. Drug Res."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1016\/j.carbpol.2012.03.072","article-title":"Inclusion complex of methyl-\u03b2-cyclodextrin and olanzapine as potential drug delivery system for schizophrenia","volume":"89","author":"Rolim","year":"2012","journal-title":"Carbohydr. Polym."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.jconrel.2004.01.005","article-title":"Preparation, characterization and in vitro release kinetics of clozapine solid lipid nanoparticles","volume":"95","author":"Venkateswarlu","year":"2004","journal-title":"J. Control. Release"},{"key":"ref_138","first-page":"126","article-title":"Novel nanoemulsion as vehicles for transdermal delivery of clozapine, in vitro in vivo studies","volume":"5","author":"Shafaat","year":"2013","journal-title":"Int. J. Pharm. Pharm. Sci."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1080\/10837450.2016.1200615","article-title":"How can lipid nanocarriers improve transdermal delivery of olanzapine?","volume":"22","author":"Iqbal","year":"2017","journal-title":"Pharm. Dev. Technol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1166\/jbn.2014.1817","article-title":"Nanoencapsulation of olanzapine increases its efficacy in antipsychotic treatment and reduces adverse effects","volume":"10","author":"Dimer","year":"2014","journal-title":"J. Biomed. Nanotechnol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.ijpharm.2018.02.010","article-title":"DoE based Olanzapine loaded poly-caprolactone nanoparticles decreases extrapyramidal effects in rodent model","volume":"541","author":"Joseph","year":"2018","journal-title":"Int. J. Pharm."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1166\/jnn.2017.12588","article-title":"Aripiprazole nanocrystal impregnated buccoadhesive films for schizophrenia","volume":"17","year":"2017","journal-title":"J. Nanosci. Nanotechnol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"3355","DOI":"10.2147\/DDDT.S150774","article-title":"Risperidone mucoadhesive buccal tablets: Formulation design, optimization and evaluation","volume":"11","year":"2017","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/j.ijpharm.2012.07.058","article-title":"Long-term stability, biocompatibility and oral delivery potential of risperidone-loaded solid lipid nanoparticles","volume":"436","author":"Silva","year":"2012","journal-title":"Int. J. Pharm."},{"key":"ref_145","first-page":"1","article-title":"The use of experimental design in the optimization of risperidone biodegradable nanoparticles: In vitro and in vivo study","volume":"45","author":"Alzubaidi","year":"2016","journal-title":"Artif. Cells Nanomed. Biotechnol."},{"key":"ref_146","first-page":"212","article-title":"Targeted brain delivery of iloperidone nanostructured lipid carriers following intranasal administration: In vivo pharmacokinetics and brain distribution studies","volume":"1","author":"Mandpe","year":"2013","journal-title":"J. Nanopharm. Drug Deliv."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.ijpharm.2017.05.051","article-title":"Parenteral nanoemulsions of risperidone for enhanced brain delivery in acute psychosis: Physicochemical and in vivo performances","volume":"533","author":"Markovic","year":"2017","journal-title":"Int. J. Pharm."},{"key":"ref_148","first-page":"146","article-title":"Long term use of lithium and factors associated with treatment response among patients with bipolar disorder","volume":"28","author":"Shan","year":"2016","journal-title":"Psychiatr. Danub."},{"key":"ref_149","doi-asserted-by":"crossref","unstructured":"Won, E., and Kim, Y.-K. (2017). An oldie but goodie: Lithium in the treatment of bipolar disorder through neuroprotective and neurotrophic mechanisms. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18122679"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1080\/10717544.2018.1428243","article-title":"Therapeutic strategies and nano-drug delivery applications in management of ageing Alzheimer\u2019s disease","volume":"25","author":"Karthivashan","year":"2018","journal-title":"Drug Deliv."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/j.bbadis.2013.09.010","article-title":"The Alzheimer\u2019s disease mitochondrial cascade hypothesis: Progress and perspectives","volume":"1842","author":"Swerdlow","year":"2014","journal-title":"Biochim. Biophys. Acta (BBA) Mol. Basis Dis."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1080\/03639045.2019.1593439","article-title":"Formulation and optimization of intranasal nanolipid carriers of pioglitazone for the repurposing in Alzheimer\u2019s disease using Box-Behnken design","volume":"45","author":"Jojo","year":"2019","journal-title":"Drug Dev. Ind. Pharm."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.colsurfb.2017.01.031","article-title":"Nose-to-brain delivery of BACE1 siRNA loaded in solid lipid nanoparticles for Alzheimer\u2019s therapy","volume":"152","author":"Rassu","year":"2017","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.jconrel.2018.04.034","article-title":"Systemic delivery of BACE1 siRNA through neuron-targeted nanocomplexes for treatment of Alzheimer\u2019s disease","volume":"279","author":"Wang","year":"2018","journal-title":"J. Control. Release"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.biomaterials.2015.11.060","article-title":"Brain-targeted co-delivery of therapeutic gene and peptide by multifunctional nanoparticles in Alzheimer\u2019s disease mice","volume":"80","author":"Liu","year":"2016","journal-title":"Biomaterials"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.2174\/1389201019666180226152542","article-title":"A dual targeting drug delivery system for penetrating blood-brain barrier and selectively delivering siRNA to neurons for Alzheimer\u2019s disease treatment","volume":"18","author":"Zhang","year":"2018","journal-title":"Curr. Pharm. Biotechnol."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.jconrel.2014.04.010","article-title":"Engineering theranostic nanovehicles capable of targeting cerebrovascular amyloid deposits","volume":"185","author":"Agyare","year":"2014","journal-title":"J. Control. Release"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.colsurfb.2016.04.041","article-title":"Cellular uptake of PLGA nanoparticles targeted with anti-amyloid and anti-transferrin receptor antibodies for Alzheimer\u2019s disease treatment","volume":"145","author":"Loureiro","year":"2016","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.jconrel.2014.07.050","article-title":"The potential use of H102 peptide-loaded dual-functional nanoparticles in the treatment of Alzheimer\u2019s disease","volume":"192","author":"Zhang","year":"2014","journal-title":"J. Control. Release"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"6519","DOI":"10.1016\/j.biomaterials.2010.04.044","article-title":"Lipid-based nanoparticles with high binding affinity for amyloid-\u03b21\u201342 peptide","volume":"31","author":"Gobbi","year":"2010","journal-title":"Biomaterials"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"14022","DOI":"10.1523\/JNEUROSCI.0284-14.2014","article-title":"Multifunctional liposomes reduce brain\u2014amyloid burden and ameliorate memory impairment in Alzheimer\u2019s disease mouse models","volume":"34","author":"Balducci","year":"2014","journal-title":"J. Neurosci."},{"key":"ref_162","doi-asserted-by":"crossref","unstructured":"Tanifum, E.A., Dasgupta, I., Srivastava, M., Bhavane, R.C., Sun, L., Berridge, J., Pourgarzham, H., Kamath, R., Espinosa, G., and Cook, S.C. (2012). Intravenous delivery of targeted liposomes to amyloid-\u03b2 pathology in APP\/PSEN1 transgenic mice. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0048515"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1021\/nn4058215","article-title":"Lipoprotein-based nanoparticles rescue the memory loss of mice with Alzheimer\u2019s disease by accelerating the clearance of amyloid-beta","volume":"8","author":"Song","year":"2014","journal-title":"ACS Nano"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1097\/NEN.0b013e318225038c","article-title":"Targeting vascular amyloid in arterioles of Alzheimer disease transgenic mice with amyloid \u03b2 protein antibody-coated nanoparticles","volume":"70","author":"Poduslo","year":"2011","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"7194","DOI":"10.1016\/j.biomaterials.2012.06.063","article-title":"Delivery of gold nanoparticles to the brain by conjugation with a peptide that recognizes the transferrin receptor","volume":"33","author":"Prades","year":"2012","journal-title":"Biomaterials"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1002\/chem.201404562","article-title":"Gold-nanoparticle-based multifunctional amyloid-\u03b2 inhibitor against Alzheimer\u2019s disease","volume":"21","author":"Gao","year":"2015","journal-title":"Chem. A Eur. J."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.colsurfb.2013.08.029","article-title":"Gold nanoparticles as amyloid-like fibrillogenesis inhibitors","volume":"112","author":"Hsieh","year":"2013","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1016\/j.actbio.2012.01.035","article-title":"Antibody-conjugated PEGylated cerium oxide nanoparticles for specific targeting of A\u03b2 aggregates modulate neuronal survival pathways","volume":"8","author":"Cimini","year":"2012","journal-title":"Acta Biomater."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s40199-018-0221-5","article-title":"Nicotinamide loaded functionalized solid lipid nanoparticles improves cognition in Alzheimer\u2019s disease animal model by reducing Tau hyperphosphorylation","volume":"26","author":"Vakilinezhad","year":"2018","journal-title":"DARU J. Pharm. Sci."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"541","DOI":"10.2174\/1567201810666131113102037","article-title":"Preparation and characterization of methylene blue nanoparticles for Alzheimer\u2019s disease and other tauopathies","volume":"11","author":"Jinwal","year":"2014","journal-title":"Curr. Drug Deliv."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"12833","DOI":"10.1021\/acsomega.9b01411","article-title":"Protein-capped metal nanoparticles inhibit Tau aggregation in Alzheimer\u2019s disease","volume":"4","author":"Sonawane","year":"2019","journal-title":"ACS Omega"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.3109\/10717544.2015.1089956","article-title":"Galantamine-loaded solid\u2013lipid nanoparticles for enhanced brain delivery: Preparation, characterization, in vitro and in vivo evaluations","volume":"23","author":"Misra","year":"2015","journal-title":"Drug Deliv."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.etap.2012.04.012","article-title":"Pharmacokinetic behavior and efficiency of acetylcholinesterase inhibition in rat brain after intranasal administration of galanthamine hydrobromide loaded flexible liposomes","volume":"34","author":"Li","year":"2012","journal-title":"Environ. Toxicol. Pharmacol."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"12076","DOI":"10.1039\/C5NR03474D","article-title":"Galantamine-loaded PLGA nanoparticles, from nano-emulsion templating, as novel advanced drug delivery systems to treat neurodegenerative diseases","volume":"7","author":"Fornaguera","year":"2015","journal-title":"Nanoscale"},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"3111","DOI":"10.3109\/10717544.2016.1153748","article-title":"Pharmacological, toxicological and neuronal localization assessment of galantamine\/chitosan complex nanoparticles in rats: Future potential contribution in Alzheimer\u2019s disease management","volume":"23","author":"Hanafy","year":"2016","journal-title":"Drug Deliv."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.3109\/03639045.2015.1062897","article-title":"Complexation as an approach to entrap cationic drugs into cationic nanoparticles administered intranasally for Alzheimer\u2019s disease management: Preparation and detection in rat brain","volume":"41","author":"Hanafy","year":"2015","journal-title":"Drug Dev. Ind. Pharm."},{"key":"ref_177","doi-asserted-by":"crossref","unstructured":"Ullah, Z., Al Asmari, A.K., Tariq, M., and Fatani, A. (2016). Preparation, characterization, and in vivo evaluation of intranasally administered liposomal formulation of donepezil. Drug Des. Dev. Ther., 205\u2013215.","DOI":"10.2147\/DDDT.S93937"},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.ijbiomac.2014.03.022","article-title":"Donepezil nanosuspension intended for nose to brain targeting: In vitro and in vivo safety evaluation","volume":"67","author":"Bhavna","year":"2014","journal-title":"Int. J. Biol. Macromol."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"3471","DOI":"10.1080\/10717544.2016.1196767","article-title":"Novel anionic polymer as a carrier for CNS delivery of anti-Alzheimer drug","volume":"23","author":"Jakki","year":"2016","journal-title":"Drug Deliv."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s00702-016-1527-4","article-title":"Donepezil loaded PLGA-b-PEG nanoparticles: Their ability to induce destabilization of amyloid fibrils and to cross blood brain barrier in vitro","volume":"124","author":"Baysal","year":"2017","journal-title":"J. Neural Transm."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1248\/cpb.58.656","article-title":"Preparation, optimization and characteristic of huperzine a loaded nanostructured lipid carriers","volume":"58","author":"Yang","year":"2010","journal-title":"Chem. Pharm. Bull."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.ijpharm.2013.02.014","article-title":"Comparative in vitro and in vivo evaluation of lipid based nanocarriers of Huperzine A","volume":"446","author":"Patel","year":"2013","journal-title":"Int. J. Pharm."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"9217","DOI":"10.2147\/IJN.S214657","article-title":"The optimization design of lactoferrin loaded hupa nanoemulsion for targeted drug transport via intranasal route","volume":"14","author":"Jiang","year":"2019","journal-title":"Int. J. Nanomed."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"705","DOI":"10.2147\/IJN.S151474","article-title":"Intranasal delivery of Huperzine A to the brain using lactoferrin-conjugated N-trimethylated chitosan surface-modified PLGA nanoparticles for treatment of Alzheimer\u2019s disease","volume":"13","author":"Meng","year":"2018","journal-title":"Int. J. Nanomed."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.ijpharm.2014.04.015","article-title":"Development, characterization and application of in situ gel systems for intranasal delivery of tacrine","volume":"468","author":"Qian","year":"2014","journal-title":"Int. J. Pharm."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.ejps.2011.10.002","article-title":"Albumin nanoparticles carrying cyclodextrins for nasal delivery of the anti-Alzheimer drug tacrine","volume":"44","author":"Luppi","year":"2011","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.nano.2009.04.001","article-title":"Chitosan nanoparticles as a new delivery system for the anti-Alzheimer drug tacrine","volume":"6","author":"Wilson","year":"2010","journal-title":"Nanomed. Nanotechnol. Biol. Med."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"3613","DOI":"10.1016\/j.xphs.2017.08.024","article-title":"Nose to brain delivery of rivastigmine by in situ gelling cationic nanostructured lipid carriers: Enhanced brain distribution and pharmacodynamics","volume":"106","author":"Wavikar","year":"2017","journal-title":"J. Pharm. Sci."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"393","DOI":"10.2147\/IJN.S39232","article-title":"Potential therapeutic effect of nanobased formulation of rivastigmine on rat model of Alzheimer\u2019s disease","volume":"8","author":"Ismail","year":"2013","journal-title":"Int. J. Nanomed."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"287","DOI":"10.2478\/v10007-008-0014-3","article-title":"A study of rivastigmine liposomes for delivery into the brain through intranasal route","volume":"58","author":"Arumugam","year":"2008","journal-title":"Acta Pharm."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.ijpharm.2013.05.009","article-title":"Enhanced brain distribution and pharmacodynamics of rivastigmine by liposomes following intranasal administration","volume":"452","author":"Yang","year":"2013","journal-title":"Int. J. Pharm."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"775","DOI":"10.3109\/03639045.2010.541262","article-title":"New perspective for the treatment of Alzheimer diseases: Liposomal rivastigmine formulations","volume":"37","author":"Mutlu","year":"2011","journal-title":"Drug Dev. Ind. Pharm."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.ejpb.2010.07.007","article-title":"Rivastigmine-loaded PLGA and PBCA nanoparticles: Preparation, optimization, characterization, in vitro and pharmacodynamic studies","volume":"76","author":"Joshi","year":"2010","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_194","first-page":"18","article-title":"New-fangled approach in the management of Alzheimer by formulation of polysorbate 80 coated chitosan nanoparticles of rivastigmine for brain delivery and their in vivo evaluation","volume":"2","author":"Khemariya","year":"2016","journal-title":"Int. J. Cur. Res. Med. Sci."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ejps.2012.04.013","article-title":"Development and evaluation of rivastigmine loaded chitosan nanoparticles for brain targeting","volume":"47","author":"Fazil","year":"2012","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.2217\/nnm-2018-0496","article-title":"Inhibition of p38 MAPK in the brain through nasal administration of p38 inhibitor loaded in chitosan nanocapsules","volume":"14","author":"Alleva","year":"2019","journal-title":"Nanomedicine"},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"107082","DOI":"10.1016\/j.nlm.2019.107082","article-title":"Improvement of memory deficits in the rat model of Alzheimer\u2019s disease by erythropoietin-loaded solid lipid nanoparticles","volume":"166","author":"Dara","year":"2019","journal-title":"Neurobiol. Learn. Mem."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"5459","DOI":"10.2147\/IJN.S87336","article-title":"Novel piperine-loaded Tween-integrated monoolein cubosomes as brain-targeted oral nanomedicine in Alzheimer\u2019s disease: Pharmaceutical, biological, and toxicological studies","volume":"10","author":"Elnaggar","year":"2015","journal-title":"Int. J. Nanomed."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"10801","DOI":"10.1021\/acsnano.5b03124","article-title":"GM1-modified lipoprotein-like nanoparticle: Multifunctional nanoplatform for the combination therapy of Alzheimer\u2019s disease","volume":"9","author":"Huang","year":"2015","journal-title":"ACS Nano"},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"3870","DOI":"10.1016\/j.biomaterials.2013.02.003","article-title":"Lactoferrin-modified PEG-co-PCL nanoparticles for enhanced brain delivery of NAP peptide following intranasal administration","volume":"34","author":"Liu","year":"2013","journal-title":"Biomaterials"},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.actbio.2016.09.010","article-title":"Gold nanoparticle-capped mesoporous silica-based H2O2-responsive controlled release system for Alzheimer\u2019s disease treatment","volume":"46","author":"Yang","year":"2016","journal-title":"Acta Biomater."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.actbio.2015.06.035","article-title":"Sialic acid (SA)-modified selenium nanoparticles coated with a high blood\u2013brain barrier permeability peptide-B6 peptide for potential use in Alzheimer\u2019s disease","volume":"25","author":"Yin","year":"2015","journal-title":"Acta Biomater."},{"key":"ref_203","doi-asserted-by":"crossref","unstructured":"Loureiro, J.A., Andrade, S., Duarte, A., Neves, A., Queiroz, J.F., Nunes, C., Sevin, E., Fenart, L., Gosselet, F., and Coelho, M.A. (2017). Resveratrol and grape extract-loaded solid lipid nanoparticles for the treatment of Alzheimer\u2019s disease. Molecules, 22.","DOI":"10.3390\/molecules22020277"},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.biomaterials.2018.12.027","article-title":"Progressive release of mesoporous nano-selenium delivery system for the multi-channel synergistic treatment of Alzheimer\u2019s disease","volume":"197","author":"Sun","year":"2019","journal-title":"Biomaterials"},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.1021\/acs.bioconjchem.9b00505","article-title":"Lactoferrin coupled lower generation PAMAM dendrimers for brain targeted delivery of memantine in aluminum-chloride-induced Alzheimer\u2019s disease in mice","volume":"30","author":"Gothwal","year":"2019","journal-title":"Bioconjugate Chem."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.ijpharm.2015.03.001","article-title":"Solid lipid nanoparticles loaded with lipoyl\u2013memantine codrug: Preparation and characterization","volume":"485","author":"Laserra","year":"2015","journal-title":"Int. J. Pharm."},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2147\/NSA.S232517","article-title":"Loading amlodipine on diamond nanoparticles: A novel drug delivery system","volume":"12","author":"Alawdi","year":"2019","journal-title":"Nanotechnol. Sci. Appl."},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.colsurfb.2015.06.025","article-title":"A novel LDL-mimic nanocarrier for the targeted delivery of curcumin into the brain to treat Alzheimer\u2019s disease","volume":"134","author":"Meng","year":"2015","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.actbio.2020.03.029","article-title":"Neuronal mitochondria-targeted delivery of curcumin by biomimetic engineered nanosystems in Alzheimer\u2019s disease mice","volume":"108","author":"Gao","year":"2020","journal-title":"Acta Biomater."},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.2147\/IJN.S128396","article-title":"Wheat germ agglutinin-conjugated liposomes incorporated with cardiolipin to improve neuronal survival in Alzheimer\u2019s disease treatment","volume":"12","author":"Kuo","year":"2017","journal-title":"Int. J. Nanomed."},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jphotobiol.2018.11.008","article-title":"A novel synthesis of selenium nanoparticles encapsulated PLGA nanospheres with curcumin molecules for the inhibition of amyloid \u03b2 aggregation in Alzheimer\u2019s disease","volume":"190","author":"Huo","year":"2019","journal-title":"J. Photochem. Photobiol. B Biol."},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1016\/j.biomaterials.2013.10.075","article-title":"Multimodal nanoprobes to target cerebrovascular amyloid in Alzheimer\u2019s disease brain","volume":"35","author":"Jaruszewski","year":"2013","journal-title":"Biomaterials"},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"910","DOI":"10.3389\/fphar.2019.00910","article-title":"Successful brain delivery of andrographolide loaded in human albumin nanoparticles to TgCRND8 mice, an Alzheimer\u2019s disease mouse model","volume":"10","author":"Bilia","year":"2019","journal-title":"Front. Pharmacol."},{"key":"ref_214","doi-asserted-by":"crossref","unstructured":"Al-Azzawi, S., Masheta, D., Guildford, A., Phillips, G., and Santin, M. (2018). Dendrimeric poly(epsilon-lysine) delivery systems for the enhanced permeability of flurbiprofen across the blood-brain barrier in Alzheimer\u2019s disease. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19103224"},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.ejps.2016.05.012","article-title":"Intranasal delivery of nanoparticle encapsulated tarenflurbil: A potential brain targeting strategy for Alzheimer\u2019s disease","volume":"92","author":"Muntimadugu","year":"2016","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"117861","DOI":"10.1016\/j.lfs.2020.117861","article-title":"Metformin loaded phosphatidylserine nanoliposomes improve memory deficit and reduce neuroinflammation in streptozotocin-induced Alzheimer\u2019s disease model","volume":"255","author":"Saffari","year":"2020","journal-title":"Life Sci."},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.ijpharm.2018.06.031","article-title":"Amino acid conjugated chitosan nanoparticles for the brain targeting of a model dipeptidyl peptidase-4 inhibitor","volume":"547","author":"Fernandes","year":"2018","journal-title":"Int. J. Pharm."},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"5954","DOI":"10.1016\/j.biomaterials.2014.03.082","article-title":"Protection of SK-N-MC cells against \u03b2-amyloid peptide-induced degeneration using neuron growth factor-loaded liposomes with surface lactoferrin","volume":"35","author":"Kuo","year":"2014","journal-title":"Biomaterials"},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"147","DOI":"10.3109\/1061186X.2014.965716","article-title":"Targeting delivery of liposomes with conjugated p-aminophenyl-\u03b1-d-manno-pyranoside and apolipoprotein E for inhibiting neuronal degeneration insulted with \u03b2-amyloid peptide","volume":"23","author":"Kuo","year":"2014","journal-title":"J. Drug Target."},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1002\/jps.24081","article-title":"Neuroprotection against degeneration of SK-N-MC cells using neuron growth factor-encapsulated liposomes with surface cereport and transferrin","volume":"103","author":"Kuo","year":"2014","journal-title":"J. Pharm. Sci."},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.ijpharm.2013.11.049","article-title":"Intranasal nanoparticles of basic fibroblast growth factor for brain delivery to treat Alzheimer\u2019s disease","volume":"461","author":"Zhang","year":"2014","journal-title":"Int. J. Pharm."},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1002\/cnma.201900468","article-title":"Pep-lipid cubosomes and vesicles compartmentalized by micelles from self-assembly of multiple neuroprotective building blocks including a large peptide hormone PACAP-DHA","volume":"5","author":"Angelova","year":"2019","journal-title":"ChemNanoMat"},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"22387","DOI":"10.1039\/C9NR08194A","article-title":"Nontoxic amphiphilic carbon dots as promising drug nanocarriers across the blood\u2013brain barrier and inhibitors of \u03b2-amyloid","volume":"11","author":"Leblanc","year":"2019","journal-title":"Nanoscale"},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"e1800340","DOI":"10.1002\/mabi.201800340","article-title":"Efficient cholera toxin B subunit-based nanoparticles with MRI capability for drug delivery to the brain following intranasal administration","volume":"19","author":"Chen","year":"2018","journal-title":"Macromol. Biosci."},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1166\/jbn.2018.2512","article-title":"Magnetic nanoparticles associated PEG\/PLGA block copolymer targeted with anti-transferrin receptor antibodies for Alzheimer\u2019s disease","volume":"14","author":"Cui","year":"2018","journal-title":"J. Biomed. Nanotechnol."},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1166\/jbn.2016.2193","article-title":"Guidance of magnetic nanocontainers for treating Alzheimer\u2019s disease using an electromagnetic, targeted drug-delivery actuator","volume":"12","author":"Do","year":"2016","journal-title":"J. Biomed. Nanotechnol."},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1021\/acschemneuro.8b00622","article-title":"Impact of gold nanoparticles on amyloid \u03b2-induced Alzheimer\u2019s disease in a rat animal model: Involvement of STIM proteins","volume":"10","author":"Sanati","year":"2019","journal-title":"ACS Chem. Neurosci."},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1517\/17425247.2014.952627","article-title":"Blood\u2013brain barrier drug delivery of IgG fusion proteins with a transferrin receptor monoclonal antibody","volume":"12","author":"Pardridge","year":"2014","journal-title":"Expert Opin. Drug Deliv."},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"969","DOI":"10.3389\/fphar.2017.00969","article-title":"\u03b2-Sheet breaker peptide-HPYD for the treatment of Alzheimer\u2019s disease: Primary studies on behavioral test and transcriptional profiling","volume":"8","author":"Liu","year":"2018","journal-title":"Front. Pharmacol."},{"key":"ref_230","doi-asserted-by":"crossref","first-page":"3837","DOI":"10.1007\/s11095-015-1744-9","article-title":"Intranasal H102 peptide-loaded liposomes for brain delivery to treat Alzheimer\u2019s disease","volume":"32","author":"Zheng","year":"2015","journal-title":"Pharm. Res."},{"key":"ref_231","doi-asserted-by":"crossref","first-page":"5499","DOI":"10.1002\/adma.201502227","article-title":"Nanotheranostics: Congo Red\/Rutin-MNPs with enhanced magnetic resonance imaging and H2O2-responsive therapy of alzheimer\u2019s disease in APPswe\/PS1dE9 transgenic mice","volume":"27","author":"Hu","year":"2015","journal-title":"Adv. Mater."},{"key":"ref_232","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12951-020-00626-1","article-title":"Neuron tau-targeting biomimetic nanoparticles for curcumin delivery to delay progression of Alzheimer\u2019s disease","volume":"18","author":"Gao","year":"2020","journal-title":"J. Nanobiotechnol."},{"key":"ref_233","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12937-016-0179-4","article-title":"Potential neuroprotective properties of epigallocatechin-3-gallate (EGCG)","volume":"15","author":"Singh","year":"2015","journal-title":"Nutr. J."},{"key":"ref_234","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jconrel.2018.05.011","article-title":"Nose-to-brain drug delivery: An update on clinical challenges and progress towards approval of anti-Alzheimer drugs","volume":"281","author":"Agrawal","year":"2018","journal-title":"J. Control. Release"},{"key":"ref_235","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1517\/17425247.2014.894504","article-title":"Optimised nanoformulation of bromocriptine for direct nose-to-brain delivery: Biodistribution, pharmacokinetic and dopamine estimation by ultra-HPLC\/mass spectrometry method","volume":"11","author":"Md","year":"2014","journal-title":"Expert Opin. Drug Deliv."},{"key":"ref_236","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.jconrel.2015.03.024","article-title":"Nanoparticle-mediated growth factor delivery systems: A new way to treat Alzheimer\u2019s disease","volume":"206","author":"Lauzon","year":"2015","journal-title":"J. Control. Release"}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/25\/22\/5294\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:32:57Z","timestamp":1760178777000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/25\/22\/5294"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,13]]},"references-count":236,"journal-issue":{"issue":"22","published-online":{"date-parts":[[2020,11]]}},"alternative-id":["molecules25225294"],"URL":"https:\/\/doi.org\/10.3390\/molecules25225294","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,13]]}}}